Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/28/2020 11:07 PDT] Turning Point Therapeutics, Inc. (NASDAQ:TPTX), Up By 100.00% ($48.64) After BUYINS.NET SqueezeTrigger Report Released on Friday, April 17th 2020 at a Price of $48.640.
• [05/22/2020 07:37 PDT] TPTX Expected to Trade Up After Bullish Patterns Develop
• [05/19/2020 08:07 PDT] TPTX Expected to Trade Up After Bullish Patterns Develop
• [04/17/2020 08:16 PDT] TPTX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [03/31/2020 08:13 PDT] TPTX Expected to Trade Down After Bearish Patterns Develop